177 related articles for article (PubMed ID: 38478491)
1. Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic.
Zafarnejad R; Chen Q; Griffin PM
PLoS One; 2024; 19(3):e0299401. PubMed ID: 38478491
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.
Ramos M; Gerlier L; Uster A; Muttram L; Frankel AH; Lamotte M
J Med Econ; 2024; 27(1):777-785. PubMed ID: 38758099
[TBL] [Abstract][Full Text] [Related]
3. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
Cusick MM; Tisdale RL; Chertow GM; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2023 Jun; 176(6):788-797. PubMed ID: 37216661
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.
Ishigami J; Padula WV; Grams ME; Chang AR; Jaar B; Gansevoort RT; Bridges JFP; Kovesdy CP; Uchida S; Coresh J; Matsushita K
Am J Kidney Dis; 2019 Jul; 74(1):23-35. PubMed ID: 30898360
[TBL] [Abstract][Full Text] [Related]
6. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
Tisdale RL; Cusick MM; Aluri KZ; Handley TJ; Joyner AKC; Salomon JA; Chertow GM; Goldhaber-Fiebert JD; Owens DK
J Gen Intern Med; 2022 Oct; 37(13):3380-3387. PubMed ID: 35137296
[TBL] [Abstract][Full Text] [Related]
8. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of population-based screening for microalbuminuria in people with type 2 diabetes mellitus in India.
Mathan Kumar S; Essakky S; Rajasulochana SR; Kar SS; Sivanatham P; Anandraj J; Parameswaran S; Soman B; Rajsekhar K; Stanley A
Int J Technol Assess Health Care; 2023 Nov; 39(1):e66. PubMed ID: 37960938
[TBL] [Abstract][Full Text] [Related]
10. Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.
Rossing P; Groehl F; Mernagh P; Folkerts K; Garreta-Rufas A; Harris J; Meredith K; Carter M; Åkerborg Ö; Wanner C; Hobbs FDR
J Med Econ; 2023; 26(1):935-943. PubMed ID: 37439218
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
Critselis E; Vlahou A; Stel VS; Morton RL
Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
[TBL] [Abstract][Full Text] [Related]
13. The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling.
Hiragi S; Tamura H; Goto R; Kuroda T
BMC Med Inform Decis Mak; 2018 Nov; 18(1):94. PubMed ID: 30413200
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of primary screening for CKD: a systematic review.
Komenda P; Ferguson TW; Macdonald K; Rigatto C; Koolage C; Sood MM; Tangri N
Am J Kidney Dis; 2014 May; 63(5):789-97. PubMed ID: 24529536
[TBL] [Abstract][Full Text] [Related]
16. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
Hoerger TJ; Wittenborn JS; Segel JE; Burrows NR; Imai K; Eggers P; Pavkov ME; Jordan R; Hailpern SM; Schoolwerth AC; Williams DE;
Am J Kidney Dis; 2010 Mar; 55(3):463-73. PubMed ID: 20116910
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.
Chen Q; Fan Y; Huang K; Li W; Geldsetzer P; Bärnighausen T; Yang T; Wang C; Chen S
Lancet Reg Health West Pac; 2024 May; 46():101065. PubMed ID: 38721063
[TBL] [Abstract][Full Text] [Related]
19. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
